Followers | 125 |
Posts | 14625 |
Boards Moderated | 2 |
Alias Born | 04/26/2013 |
![](https://investorshub.advfn.com/uicon/395980.png?cb=1699265709)
Wednesday, October 04, 2023 7:29:27 AM
***FOLLOW FOR ALERTS***
Recent OKYO News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/08/2024 11:00:21 AM
- OKYO Pharma Announces Participation in May 2024 Investor Conferences • GlobeNewswire Inc. • 05/08/2024 11:00:00 AM
- OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO) • GlobeNewswire Inc. • 04/30/2024 11:00:00 AM
- OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024 • GlobeNewswire Inc. • 04/08/2024 11:00:00 PM
- OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery • GlobeNewswire Inc. • 04/02/2024 11:00:00 AM
- OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101 • GlobeNewswire Inc. • 03/22/2024 11:00:00 AM
- OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial • GlobeNewswire Inc. • 03/21/2024 11:00:00 AM
- OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event • GlobeNewswire Inc. • 03/20/2024 11:00:00 AM
- OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain • InvestorsHub NewsWire • 02/09/2024 12:36:59 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/09/2024 12:00:36 PM
- OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain • GlobeNewswire Inc. • 02/09/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/31/2024 12:00:20 PM
- OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board • GlobeNewswire Inc. • 01/31/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/08/2024 12:00:33 PM
- OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease • GlobeNewswire Inc. • 01/08/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/05/2024 02:30:06 PM
- OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024 • GlobeNewswire Inc. • 01/05/2024 02:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/21/2023 12:35:34 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/20/2023 10:30:30 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/18/2023 09:56:45 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/04/2023 12:00:18 PM
- OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit • GlobeNewswire Inc. • 12/04/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/29/2023 12:00:36 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/01/2023 08:55:29 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/31/2023 08:59:54 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM